Cargando...
Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with th...
Guardado en:
| Publicado en: | Clin Pharmacokinet |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5904242/ https://ncbi.nlm.nih.gov/pubmed/28762135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0582-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|